化学免疫疗法
套细胞淋巴瘤
医学
淋巴瘤
队列
肿瘤科
内科学
美罗华
作者
Minna Harmanen,Mika Hujo,Reijo Sund,Marc Sorigué,Madiha Khan,Roosa Prusila,Tuula Klaavuniemi,Esa Kari,Esa Jantunen,Kaisa Sunela,Aino Rajamäki,Erika Alanne,Hanne Kuitunen,Juan‐Manuel Sancho,Arja Jukkola,Aino Rönkä,Outi Kuittinen
摘要
ABSTRACT Mantle cell lymphoma is a rare type of B‐cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.
科研通智能强力驱动
Strongly Powered by AbleSci AI